89 related articles for article (PubMed ID: 9891527)
1. Flow cytometry as a prognostic method for the identification of adenomatous hyperplasia at risk of developing endometrial carcinoma.
Lindahl B; Willén R
Anticancer Res; 1998; 18(6B):4611-2. PubMed ID: 9891527
[TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of endometrial hyperplasia in HNPCC-suspicious patients may predict progression to endometrial carcinoma.
Sutter C; Dallenbach-Hellweg G; Schmidt D; Baehring J; Bielau S; von Knebel Doeberitz M; Gebert J
Int J Gynecol Pathol; 2004 Jan; 23(1):18-25. PubMed ID: 14668545
[TBL] [Abstract][Full Text] [Related]
3. Steroid receptor concentrations as a prognostic factor in atypical endometrial hyperplasia.
Lindahl B; Willén R
Anticancer Res; 1998; 18(5B):3793-5. PubMed ID: 9854498
[TBL] [Abstract][Full Text] [Related]
4. Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors.
Susini T; Amunni G; Molino C; Carriero C; Rapi S; Branconi F; Marchionni M; Taddei G; Scarselli G
Cancer; 2007 Mar; 109(5):882-90. PubMed ID: 17262824
[TBL] [Abstract][Full Text] [Related]
5. [A study on DNA content and cell cycle phase analysis in endometrial carcinoma].
Xue F; Jiao S; Zhao F
Zhonghua Fu Chan Ke Za Zhi; 1996 Apr; 31(4):216-9. PubMed ID: 8758776
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous endometrial hyperplasia. A prospective, 5 year follow-up of 246 patients after abrasio only, including 380 patients followed-up for 2 years.
Lindahl B; Willén R
Anticancer Res; 1994; 14(5B):2141-6. PubMed ID: 7840513
[TBL] [Abstract][Full Text] [Related]
7. A strong prognostic variable in endometrial carcinoma: flow cytometric S-phase fraction.
Kaleli S; Kösebay D; Beşe T; Demirkiran F; Oz UA; Arvas M; Aydinli K; Erkün E
Cancer; 1997 Mar; 79(5):944-51. PubMed ID: 9041157
[TBL] [Abstract][Full Text] [Related]
8. DNA ploidy and S-phase fraction analyses of hyperplastic, atypical and cancerous endometrium using flow cytometry from paraffin-embedded tissues.
Pervez S; Hitchcock A; Sinton TM; Mani A; Smith JL
Pathol Res Pract; 2002; 198(1):13-7. PubMed ID: 11866205
[TBL] [Abstract][Full Text] [Related]
9. Identification of high-risk groups in endometrial carcinoma stage I-II. A combination of DNA- and steroid receptor-measurements identifies early deaths from the disease.
Lindahl B; Ranstam J; Norgren A; Willén R
Anticancer Res; 1995; 15(3):1095-100. PubMed ID: 7645932
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of cell kinetics in endometrial adenocarcinoma.
Mariani L; Conti L; Antenucci A; Vercillo M; Atlante M; Gandolfo GM
Anticancer Res; 2000; 20(5B):3569-74. PubMed ID: 11131664
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous endometrial hyperplasia. A 5 year follow-up of 82 patients after high-dose gestagen treatment.
Lindahl B; Willén R
Anticancer Res; 1994; 14(6B):2831-4. PubMed ID: 7872726
[TBL] [Abstract][Full Text] [Related]
12. Endometrial hyperplasia and carcinoma in endometrial polyps: clinicopathologic and follow-up findings.
Mittal K; Da Costa D
Int J Gynecol Pathol; 2008 Jan; 27(1):45-8. PubMed ID: 18156974
[TBL] [Abstract][Full Text] [Related]
13. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometry (FCM) analysis of endometrial hyperplasia and carcinoma.
Kysela B; Siracký J; Redecha M; Bárdos A
Neoplasma; 1990; 37(5):489-95. PubMed ID: 2234210
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
[TBL] [Abstract][Full Text] [Related]
16. Low-risk endometrial carcinoma: assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators.
Lim P; Aquino-Parsons CF; Wong F; Dupuis B; Phillips D; Zhou C; Gilks CB
Gynecol Oncol; 1999 May; 73(2):191-5. PubMed ID: 10329033
[TBL] [Abstract][Full Text] [Related]
17. [Characteristic of cystic glandular hyperplasia as a precursor of endometrial carcinoma].
Yokosuka K; Teshima H; Yamakawa Y; Hasumi K
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Nov; 46(11):1241-6. PubMed ID: 7844442
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometry in primary breast carcinomas: prognostic impact of S-phase fraction according to different analysis patterns.
Michels JJ; Marnay J; Plancoulaine B; Chasle J
Cytometry B Clin Cytom; 2004 May; 59(1):32-9. PubMed ID: 15108168
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric analysis of cell surface antigen recognized by monoclonal antibody (MSN-1) in normal, hyperplasia, and carcinoma of endometrial cells: its diagnostic value for endometrial carcinoma.
Kobayashi Y; Tsukazaki K; Ohta K; Mikami M; Kubushiro K; Nozawa S
Cytometry; 1997 Feb; 30(1):23-7. PubMed ID: 9056738
[TBL] [Abstract][Full Text] [Related]
20. Endometrial hyperplasia following estrogen treatment without the addition of gestagen. A follow-up study after withdrawal of estrogens.
Lindahl B; Willén R
Anticancer Res; 1991; 11(6):2071-3. PubMed ID: 1776842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
